Home > Gastroenterology > Sintilimab plus FOLFIRINOX may provide benefits in metastatic pancreatic cancer

Sintilimab plus FOLFIRINOX may provide benefits in metastatic pancreatic cancer

Presented By
Dr Qihan Fu, Zhejiang University School of Medicine, China
Conference
ASCO GI 2022
Trial
Phase 3, CISPD3
The health outcomes of patients with metastatic and recurrent pancreatic cancer may improve when sintilimab is added to the standard treatment regimen of modified FOLFIRINOX chemotherapy. Moreover, the phase 3 CISPD3 trial displayed a manageable safety profile of the combination therapy [1]. “(Modified) FOLFIRINOX is the standard first-line therapy for patients with metastatic pancreatic adenocarcinoma,” said Dr Qihan Fu (Zhejiang University School of Medicine, China). “The anti-PD1 monoclonal antibody sintilimab may provide additional benefits for this difficult-to-treat patient population.” The phase 3 CISPD3 trial (NCT03977272) randomised 110 patients with metastatic pancreatic cancer 1:1 to sintilimab plus modified FOLFIRINOX chemotherapy or chemotherapy alone. Patients in the sintilimab arm received 200 mg sintilimab every 3 w...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on